Delayed wound healing and impaired tissue regeneration represent significant clinical challenges, particularly in patients with diabetes, vascular insufficiency, and immunocompromised states. Conventional therapeutic approaches often exhibit limitations including antimicrobial resistance, adverse effects, and incomplete tissue restoration. Medicinal plants have emerged as promising alternatives, offering multifaceted mechanisms through bioactive phytochemicals that modulate inflammatory responses, enhance antimicrobial defense, and provide antioxidant protection. This article comprehensively examines the role of medicinal plants in promoting wound healing and tissue regeneration across preclinical and clinical models. Key themes include the identification of bioactive compounds such as flavonoids, alkaloids, terpenoids, and polyphenols, their mechanistic contributions to angiogenesis, collagen synthesis, and matrix remodeling, and the translational evidence supporting their therapeutic efficacy. Preclinical investigations utilizing in vitro cell culture systems and animal wound models have demonstrated accelerated closure rates, enhanced granulation tissue formation, and reduced microbial burden. Clinical studies have validated these findings through randomized controlled trials and observational studies, revealing favorable outcomes with various formulation strategies including hydrogels, ointments, and novel delivery systems. Despite promising results, challenges remain regarding standardization, safety profiling, pharmacokinetic characterization, and regulatory compliance. Future perspectives emphasize the integration of medicinal plant-derived therapeutics into modern regenerative medicine, leveraging nanotechnology, combination therapies, and precision medicine approaches to optimize clinical translation and address the global burden of chronic non-healing wounds.